Use of Genetic Variants Related to Antihypertensive Drugs to Inform on Efficacy and Side Effects

Drug effects can be investigated through natural variation in the genes for their protein targets. The present study aimed to use this approach to explore the potential side effects and repurposing potential of antihypertensive drugs, which are among the most commonly used medications worldwide. Gen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation (New York, N.Y.) Jg. 140; H. 4; S. 270
Hauptverfasser: Gill, Dipender, Georgakis, Marios K, Koskeridis, Fotios, Jiang, Lan, Feng, Qiping, Wei, Wei-Qi, Theodoratou, Evropi, Elliott, Paul, Denny, Joshua C, Malik, Rainer, Evangelou, Evangelos, Dehghan, Abbas, Dichgans, Martin, Tzoulaki, Ioanna
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 23.07.2019
Schlagworte:
Antihypertensive Agents - adverse effects
Antihypertensive Agents - pharmacology
Antihypertensive Agents - therapeutic use
Drug-Related Side Effects and Adverse Reactions - genetics
Humans
Pharmacogenomic Variants
Mendelian randomization analysis
antihypertensive drugs
ISSN:1524-4539, 1524-4539
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Drug effects can be investigated through natural variation in the genes for their protein targets. The present study aimed to use this approach to explore the potential side effects and repurposing potential of antihypertensive drugs, which are among the most commonly used medications worldwide. Genetic proxies for the effect of antihypertensive drug classes were identified as variants in the genes for the corresponding targets that associated with systolic blood pressure at genome-wide significance. Mendelian randomization estimates for drug effects on coronary heart disease and stroke risk were compared with randomized, controlled trial results. A phenome-wide association study in the UK Biobank was performed to identify potential side effects and repurposing opportunities, with findings investigated in the Vanderbilt University biobank (BioVU) and in observational analysis of the UK Biobank. Suitable genetic proxies for angiotensin-converting enzyme inhibitors, β-blockers, and calcium channel blockers (CCBs) were identified. Mendelian randomization estimates for their effect on coronary heart disease and stroke risk, respectively, were comparable to results from randomized, controlled trials against placebo. A phenome-wide association study in the UK Biobank identified an association of the CCB standardized genetic risk score with increased risk of diverticulosis (odds ratio, 1.02 per standard deviation increase; 95% CI, 1.01-1.04), with a consistent estimate found in BioVU (odds ratio, 1.01; 95% CI, 1.00-1.02). Cox regression analysis of drug use in the UK Biobank suggested that this association was specific to nondihydropyridine CCBs (hazard ratio 1.49 considering thiazide diuretic agents as a comparator; 95% CI, 1.04-2.14) but not dihydropyridine CCBs (hazard ratio, 1.04; 95% CI, 0.83-1.32). Genetic variants can be used to explore the efficacy and side effects of antihypertensive medications. The identified potential effect of nondihydropyridine CCBs on diverticulosis risk could have clinical implications and warrants further investigation.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1524-4539
1524-4539
DOI:10.1161/CIRCULATIONAHA.118.038814